Healthequity (HQY) Price Target Raised to $60.00
Healthequity (NASDAQ:HQY) had its target price hoisted by Cantor Fitzgerald from $56.00 to $60.00 in a research report sent to investors on Wednesday morning. They currently have an overweight rating on the stock.
A number of other equities research analysts also recently issued reports on HQY. Zacks Investment Research raised shares of Healthequity from a hold rating to a buy rating and set a $58.00 price target on the stock in a research note on Wednesday, October 11th. BidaskClub downgraded shares of Healthequity from a hold rating to a sell rating in a research note on Wednesday, October 18th. Chardan Capital upped their price target on shares of Healthequity from $58.00 to $62.00 and gave the company a buy rating in a research note on Wednesday, December 6th. Citigroup began coverage on shares of Healthequity in a research note on Thursday, January 4th. They set a buy rating on the stock. Finally, JPMorgan Chase & Co. decreased their price target on shares of Healthequity from $52.00 to $51.00 and set an overweight rating on the stock in a research note on Wednesday, January 24th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $57.17.
Healthequity (NASDAQ:HQY) opened at $49.93 on Wednesday. Healthequity has a 1-year low of $37.62 and a 1-year high of $55.31. The company has a market cap of $3,121.61, a price-to-earnings ratio of 67.47, a PEG ratio of 1.99 and a beta of 1.70.
In other Healthequity news, insider Jon Kessler sold 40,000 shares of the business’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $49.47, for a total transaction of $1,978,800.00. Following the transaction, the insider now owns 485,000 shares in the company, valued at $23,992,950. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Ashley Dreier sold 12,000 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $52.00, for a total transaction of $624,000.00. Following the transaction, the vice president now owns 17,652 shares in the company, valued at approximately $917,904. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 371,426 shares of company stock worth $18,749,703. 29.00% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the business. Zions Bancorporation bought a new position in Healthequity during the third quarter valued at $119,000. Catalyst Capital Advisors LLC bought a new position in Healthequity during the fourth quarter valued at $149,000. CIBC Asset Management Inc bought a new position in Healthequity during the third quarter valued at $208,000. 1st Global Advisors Inc. bought a new position in Healthequity during the second quarter valued at $213,000. Finally, Shelton Capital Management bought a new position in Healthequity during the second quarter valued at $217,000. Institutional investors and hedge funds own 98.20% of the company’s stock.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.